INVESTIGADORES
VILLAVERDE Marcela Solange
capítulos de libros
Título:
The Potential of Suicide plus Immune Gene Therapy for Treating Osteosarcoma: the Experience on Canine Veterinary Patientes
Autor/es:
LILIANA M. E. FINOCCHIARO; AGUSTINA SPECTOR; URSULA A. ROSSI; MARIA L. GIL-CARDEZA; JOSE L. SUAREZ; MARIA D. RIVEROS; MARCELA S. VILLAVERDE; GERARDO C. GLIKIN
Libro:
Sarcoma: Symptoms, Causes and Treatments
Editorial:
Nova Science Publishers, Inc
Referencias:
Lugar: New York; Año: 2011;
Resumen:
Comparative oncology amalgamates the experience on naturally occurring cancers in veterinary
patients into more general studies of cancer, especially those focused on the human disease. Naturally
occurring tumors in dogs have clinical and biological similarities to human cancers that are difficult to
replicate in other model systems.
Osteosarcoma (OSA) accounts for approximately 85% of primary bone cancers in the dog. It is a
common cancer of large to giant breed dogs, and it occurs primarily in the appendicular skeleton. Being a
common and highly metastatic tumor, it does not have additional treatment options when adjuvant
chemotherapy has failed against its disseminated form. Even with removal of the primary tumor, before
spread of the cancer is clinically detectable, metastases to lung, bone, or other sites eventually develop in
almost all dogs. Palliative radiation therapy for bone pain is indicated in those dogs that do not undergo
amputation or a limb-sparing surgery. Standard treatments result in median survival rates ranging
between 78 and 130 days.
In such context the need to develop new treatments to fight OSA is compelling. While most of cancer
gene therapy for canine veterinary patients was aimed to spontaneous melanoma and some to primary
canine soft-tissue sarcomas, only one was specifically aimed to OSA. Therefore, we propose a new
treatment combining: (i) the local antiproliferative effects of interferon-â and HSV-thymidine kinase
suicide gene therapy with (ii) the systemic effects triggered by OSA antigens in an immunostimulatory
environment created by the slow secretion of granulocyte and macrophage colony-stimulating factor and
interleukin-2.
Beyond the high safety standard of the proposed treatment on six canine osteosarcoma patients, four
of them survived more than 6 months (among them, one largely exceeded 1 year). In addition, the
treatment prevented or delayed local relapse, regional metastases and distant metastases, suggesting a
strong systemic antitumor immunity.
We are presenting detailed evidences of two cases of a very successful outcome: (i) a first one
presenting a long term recurrence-free period after tumor surgical excision and (ii) a second one of a
long-lasting complete remission without surgical intervention.
As a conclusion of this work we suggest that the use of this treatment, associated or not to the
surgical removal of the tumor (depending on the initial stage of the disease), would be safe and could
delay or prevent recurrence and metastases, with the consequent quality of life and survival rate
improvement. To establish the treatment efficacy, the encouraging results presented here warrant the
proposal of a subsequent trial including a representative amount of canine patients.
suicide gene therapy with (ii) the systemic effects triggered by OSA antigens in an immunostimulatory
environment created by the slow secretion of granulocyte and macrophage colony-stimulating factor and
interleukin-2.
Beyond the high safety standard of the proposed treatment on six canine osteosarcoma patients, four
of them survived more than 6 months (among them, one largely exceeded 1 year). In addition, the
treatment prevented or delayed local relapse, regional metastases and distant metastases, suggesting a
strong systemic antitumor immunity.
We are presenting detailed evidences of two cases of a very successful outcome: (i) a first one
presenting a long term recurrence-free period after tumor surgical excision and (ii) a second one of a
long-lasting complete remission without surgical intervention.
As a conclusion of this work we suggest that the use of this treatment, associated or not to the
surgical removal of the tumor (depending on the initial stage of the disease), would be safe and could
delay or prevent recurrence and metastases, with the consequent quality of life and survival rate
improvement. To establish the treatment efficacy, the encouraging results presented here warrant the
proposal of a subsequent trial including a representative amount of canine patients.
suicide gene therapy with (ii) the systemic effects triggered by OSA antigens in an immunostimulatory
environment created by the slow secretion of granulocyte and macrophage colony-stimulating factor and
interleukin-2.
Beyond the high safety standard of the proposed treatment on six canine osteosarcoma patients, four
of them survived more than 6 months (among them, one largely exceeded 1 year). In addition, the
treatment prevented or delayed local relapse, regional metastases and distant metastases, suggesting a
strong systemic antitumor immunity.
We are presenting detailed evidences of two cases of a very successful outcome: (i) a first one
presenting a long term recurrence-free period after tumor surgical excision and (ii) a second one of a
long-lasting complete remission without surgical intervention.
As a conclusion of this work we suggest that the use of this treatment, associated or not to the
surgical removal of the tumor (depending on the initial stage of the disease), would be safe and could
delay or prevent recurrence and metastases, with the consequent quality of life and survival rate
improvement. To establish the treatment efficacy, the encouraging results presented here warrant the
proposal of a subsequent trial including a representative amount of canine patients.
suicide gene therapy with (ii) the systemic effects triggered by OSA antigens in an immunostimulatory
environment created by the slow secretion of granulocyte and macrophage colony-stimulating factor and
interleukin-2.
Beyond the high safety standard of the proposed treatment on six canine osteosarcoma patients, four
of them survived more than 6 months (among them, one largely exceeded 1 year). In addition, the
treatment prevented or delayed local relapse, regional metastases and distant metastases, suggesting a
strong systemic antitumor immunity.
We are presenting detailed evidences of two cases of a very successful outcome: (i) a first one
presenting a long term recurrence-free period after tumor surgical excision and (ii) a second one of a
long-lasting complete remission without surgical intervention.
As a conclusion of this work we suggest that the use of this treatment, associated or not to the
surgical removal of the tumor (depending on the initial stage of the disease), would be safe and could
delay or prevent recurrence and metastases, with the consequent quality of life and survival rate
improvement. To establish the treatment efficacy, the encouraging results presented here warrant the
proposal of a subsequent trial including a representative amount of canine patients.
â and HSV-thymidine kinase
suicide gene therapy with (ii) the systemic effects triggered by OSA antigens in an immunostimulatory
environment created by the slow secretion of granulocyte and macrophage colony-stimulating factor and
interleukin-2.
Beyond the high safety standard of the proposed treatment on six canine osteosarcoma patients, four
of them survived more than 6 months (among them, one largely exceeded 1 year). In addition, the
treatment prevented or delayed local relapse, regional metastases and distant metastases, suggesting a
strong systemic antitumor immunity.
We are presenting detailed evidences of two cases of a very successful outcome: (i) a first one
presenting a long term recurrence-free period after tumor surgical excision and (ii) a second one of a
long-lasting complete remission without surgical intervention.
As a conclusion of this work we suggest that the use of this treatment, associated or not to the
surgical removal of the tumor (depending on the initial stage of the disease), would be safe and could
delay or prevent recurrence and metastases, with the consequent quality of life and survival rate
improvement. To establish the treatment efficacy, the encouraging results presented here warrant the
proposal of a subsequent trial including a representative amount of canine patients.